IPO Lockup Expiration Alert: ALX Oncology Holdings Inc. (ALXO)
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of Burlingame, California-based ALX Oncology Holdings Inc. (ALXO) ends on January 13.
ALX Oncology Holdings is a clinical-stage immuno-oncology company developing therapies targeting CD47 checkpoint pathway for blood and solid tumor cancers.
The company s lead product candidate is ALX148, a next-generation CD47 blocking therapeutic, which is being studied across a variety of cancers.
2021 is expected to be another productive year with additional clinical trial initiations and data readouts, according to ALX Oncology. Anticipated Milestones for 2021
. Phase 1b full data read out for ALX148 in combination with Merck s Keytruda and chemotherapy for the treatment of patients with head and neck squamous cell carcinoma (HNSCC) is planned in the first half of 2021.
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Affirm priced its initial public offering of class A common stock at $49.00 per share. The company is offering 24.6 million shares of its class A common stock.
[NEW YORK] Affirm Holdings, which provides installment loans to online shoppers, priced its US initial public offering (IPO) above its marketed range to raise US$1.2 billion. Read more at The Business Times.
/PRNewswire/ DocuSign, Inc. (Nasdaq: DOCU) today announced that it has priced $600.0 million aggregate principal amount of 0% convertible senior notes due.